CLB vs EGY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CLB exhibits a concerning divergence between its current market price ($17.45) and its deterministic value markers, with a Piotroski F-Score of 4/9 indicating only stable health. The stock is trading at a significant premium to both its Graham Number ($9.04) and Intrinsic Value ($4.41), while experiencing a sharp YoY earnings decline of 31.60%. Despite a strong 1-year price rally, the underlying fundamentals—specifically the negative earnings growth and bearish technical trend—suggest the current valuation is unsustainable.
EGY exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health. The company is struggling with negative profit margins (-11.52%) and a significant decline in year-over-year revenue (-25.20%). While analysts maintain a 'strong_buy' rating with a target of $8.80, this is sharply contradicted by a bearish technical trend (10/100) and an unsustainable dividend payout ratio of 92.59%. The disconnect between analyst optimism and deteriorating hard data suggests a high-risk profile.
Compare Another Pair
Related Comparisons
CLB vs EGY: Head-to-Head Comparison
This page compares Core Laboratories Inc. (CLB) and VAALCO Energy, Inc. (EGY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.